Mobidiag raises additional EUR 4 million
The Finnish molecular diagnostics company Mobidiag has closed a four-million-euro funding round supported by Finnish investment service company Springvest.
The funding round was successfully brought to its conclusion before the closing date, with participation from more than 200 investors.
Mobidiag will use the funding for its global business development and to scale up the production of its Novodiag solution.
“Thanks to innovative product releases and significant support from our investors, Mobidiag is an acknowledged partner and a key player in the highly competitive market of molecular diagnostics,” says CEO Tuomas Tenkanen. “This translates clearly through this new public financing round which we successfully completed in less than three weeks. We are very happy that Springvest has been able to support us again in this process and to witness with us such great involvement from investors.”
Mobidiag’s solutions detect infectious diseases, gastrointestinal infections, and multi-drug resistant organisms, or ‘superbugs’. The company’s current product lines include Amplidiag and Novodiag, which are suited for all types of laboratories, and are both affordable and fast.